Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2018 to Q4 2025

Type / Class
Equity / American Depositary Shares, each representing one ordinary share, par value $0.000042 per share
Symbol
AUTL on Nasdaq
Shares outstanding
265,957,447
Price per share
$1.43
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
139,213,138
Total reported value
$276,805,785
% of total 13F portfolios
0%
Share change
-2,237,026
Value change
-$2,112,631
Number of holders
89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAK Capital Fund LP 11% +12% $41,107,320 +$4,271,434 30,005,343 +12% MAK Capital Fund LP 31 Dec 2025
Syncona Portfolio Ltd 11% $37,755,579 28,821,053 Syncona Portfolio Limited 31 Mar 2025
ARMISTICE CAPITAL, LLC 6.6% +12% $25,025,000 +$2,717,000 17,500,000 +12% Armistice Capital, LLC 31 Dec 2025
FMR LLC 3.8% $13,312,676 10,162,348 FMR LLC 31 Mar 2025
Deep Track Capital, LP 0.97% $4,186,839 2,568,613 Deep Track Capital, LP 30 Sep 2025

As of 31 Dec 2025, 89 institutional investors reported holding 139,213,138 shares of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL). This represents 52% of the company’s total 265,957,447 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MAK CAPITAL ONE LLC 11% 30,005,343 +15% 8% $59,710,633
Blackstone Inc. 7.7% 20,485,611 0% 0.18% $40,766,366
ARMISTICE CAPITAL, LLC 6.6% 17,500,000 +12% 0.85% $34,825,000
Syncona Portfolio Ltd 6.3% 16,640,720 0% 96% $33,115,033
Tetragon Partners GP Ltd 3.6% 9,500,000 0% 4% $18,905,000
SCHRODER INVESTMENT MANAGEMENT GROUP 3.6% 9,489,345 +13% 0.01% $18,694,010
Frazier Life Sciences Management, L.P. 1.7% 4,623,324 0% 0.25% $9,200,415
BlackRock, Inc. 1.4% 3,685,825 +6.1% 0% $7,334,792
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.3% 3,361,156 0.01% $6,689,000
Laurion Capital Management LP 1.2% 3,316,626 0% 0.45% $6,600,086
RENAISSANCE TECHNOLOGIES LLC 1.2% 3,105,404 -36% 0.01% $6,179,754
BANK OF AMERICA CORP /DE/ 0.74% 1,960,766 -3.4% 0% $3,901,924
ACADIAN ASSET MANAGEMENT LLC 0.68% 1,804,117 -2.7% 0.01% $3,580,000
MORGAN STANLEY 0.53% 1,397,251 +15% 0% $2,780,530
Atle Fund Management AB 0.44% 1,169,634 0% 0.74% $2,327,571
CITADEL ADVISORS LLC 0.44% 1,159,791 -81% 0% $2,307,984
Cetera Investment Advisers 0.41% 1,099,750 +37% 0% $2,188,503
JPMORGAN CHASE & CO 0.37% 979,275 +8.4% 0% $1,948,757
UBS Group AG 0.33% 877,100 +114% 0% $1,745,429
Alphabet Inc. 0.26% 698,262 0% 0.05% $1,389,541
JANE STREET GROUP, LLC 0.26% 681,000 -22% 0% $1,355,190
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.23% 598,987 +154% 0% $1,191,984
Hennion & Walsh Asset Management, Inc. 0.17% 453,828 +7.9% 0.03% $903,118
Privium Fund Management B.V. 0.12% 326,245 +5.6% 0.12% $649,228
Point72 Asset Management, L.P. 0.11% 305,359 0% $607,664

Institutional Holders of Autolus Therapeutics plc - American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (AUTL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 139,213,138 $276,805,785 -$2,112,631 $1.99 89
2025 Q3 143,579,673 $233,669,297 -$67,552,879 $1.63 95
2025 Q2 165,944,662 $378,376,899 +$9,844,394 $2.28 93
2025 Q1 168,007,060 $260,819,521 -$3,531,773 $1.55 93
2024 Q4 168,335,372 $395,090,875 -$37,054,930 $2.35 107
2024 Q3 178,602,235 $648,320,594 +$2,536,180 $3.63 97
2024 Q2 178,106,548 $619,765,055 -$54,511,638 $3.48 106
2024 Q1 175,580,707 $1,120,176,501 +$380,385,653 $6.38 114
2023 Q4 115,868,017 $746,230,557 +$30,259,044 $6.44 97
2023 Q3 110,707,409 $257,962,960 +$2,926,164 $2.33 67
2023 Q2 109,330,876 $260,181,467 +$12,434,850 $2.38 67
2023 Q1 105,962,470 $194,950,415 -$3,026,243 $1.84 64
2022 Q4 107,371,378 $203,976,112 +$109,842,474 $1.90 69
2022 Q3 49,366,337 $105,661,961 -$3,352,319 $2.14 62
2022 Q2 50,829,136 $143,849,865 -$7,115,566 $2.83 57
2022 Q1 45,661,103 $190,513,250 -$17,791,387 $4.17 60
2021 Q4 52,463,220 $272,271,730 +$101,855,863 $5.19 69
2021 Q3 25,076,258 $164,226,984 -$2,136,433 $6.55 55
2021 Q2 25,378,541 $169,575,110 +$23,313,452 $6.64 64
2021 Q1 22,400,702 $128,321,739 +$53,655,759 $5.73 58
2020 Q4 12,635,638 $112,960,120 +$962,285 $8.94 46
2020 Q3 12,386,365 $143,379,095 -$24,849,875 $11.64 44
2020 Q2 14,328,662 $229,696,396 -$16,435,312 $16.03 48
2020 Q1 15,977,491 $96,357,056 +$6,942,585 $5.99 50
2019 Q4 13,423,917 $177,195,289 +$748,992 $13.20 54
2019 Q3 13,444,843 $166,969,346 -$100,503,433 $12.42 42
2019 Q2 21,383,578 $344,232,698 +$52,450,982 $16.10 45
2019 Q1 18,088,058 $569,233,000 +$34,027,507 $31.47 32
2018 Q4 16,988,795 $557,884,000 -$24,061,507 $32.84 36
2018 Q3 17,853,077 $546,310,000 +$275,258,001 $30.66 39
2018 Q2 9,009,943 $241,253,000 +$237,222,000 $26.79 49